What is Short Bowel Syndrome Market?
Short bowel syndrome affects the useful capability of the internal organ. Patients suffering from short bowel syndrome have a reduced ability to soak up trace components, fats, vitamins, fluids, minerals, and carbohydrates and may expertise weight loss, malnutrition, diarrhea, and dehydration. Presently, there's no cure for brief bowel syndrome, and also the treatment is targeted towards symptoms. In very few cases, short internal organ syndrome can be life-threatening however sometimes, the diseased bowel managed through effective medication. In most cases, short bowel syndrome is related to bowel surgeries. It's generally acquired over the individualís lifespan and in barely some cases, it's a genetic incidence. Treatment principally includes nutrition & diet management, medication, and surgery. In medication, teduglutide was 1st approved by the federal agency for brief bowel syndrome disorder. Different treatments embody antidiarrheal, histamine blockers, nucleon pump inhibitors, and growth hormones.
The market study is being classified by Type (GLP-2, Growth Hormone, Glutamine and Others), by Application (Hospitals and Clinics) and major geographies with country level break-up.
Shire Plc (United States), Merck & Company, Inc. (United States), Swedish Orphan Biovitrum AB (Sweden), Novartis AG (Switzerland), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), AstraZeneca Plc (United Kingdom) and Johnson & Johnson (United States) are some of the key players profiled in the study.
State governments provide special incentives to manufacturers for the development of short bowel syndrome drugs. The development of short bowel syndrome drugs is at a nascent stage, which creates more opportunities for global players. Public-private partnerships are encouraging pharmaceutical companies to develop new orphan drugs for short bowel syndrome. A few countries have implemented a combination of legislation, regulations, and policies promoting drug development for short bowel syndrome. All these factors act as potential drivers for the growth of the short bowel syndrome market. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Short Bowel Syndrome market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Short Bowel Syndrome market by Type, Application and Region.
On the basis of geography, the market of Short Bowel Syndrome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Raising Awareness and Availability of Epidemiological Data
- Rapid Improvements in The Field of Healthcare
- A Rise in The Geriatric Population
- Adoption of The Treatment
- Increasing Recommendation by The Doctors
- High Cost of The Treatments
- Non-Profit Organizations Are Promoting Research & Development
- A Lack of Approved Treatment Options
Key Target AudienceProviders of Short Bowel Syndrome, Governmental and Regulatory bodies and End-Users
Frequently Asked Questions (FAQ):
1. Which factors would majorly drive the Short Bowel Syndrome Market?
"Raising Awareness and Availability of Epidemiological Data
" is seen as one of major growth factors of Short Bowel Syndrome Market in years to come.
2. Can we have customized study for Short Bowel Syndrome Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.